The phase 2 I-SPY2.2 trial found promising responses with rilvegostomig plus trastuzumab deruxtecan in biomarker-defined, immune-positive tumors.
Related to this article
More than 76% of US counties have no TNBC trial, and only 9.8% of rural counties have one vs 47% of metropolitan counties, a new analysis finds.
Rural breast cancer deaths rise faster than urban rates, driven by low income, later diagnosis, and treatment gaps—warning of widening disparities by 2035.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Onvansertib Receives FDA Orphan Drug Designation for CMML
2
How Is Targeted Therapy Changing Non–Small Cell Lung Cancer Treatment?
3
FDA Alignment Reached on Phase 3 Design for RGT-61159 in ACC
4
Dr Shen on Histology-Specific Trials in Lobular Breast Cancer
5